Please delete the section entitled "**DESCRIPTION OF FIGURES**" at page 11, line 28 to page 12, line12.

In the claims:

Please amend claims 11, 19 and 23, and add new claims 24-33 as follows: (All the pending claims 11-33 are recited below for the Examiner's convenience).

11. (Amended) A vaccine formulation suitable for mucosal administration, comprising: a mixture of

a) a virus-like particle (VLP) comprising a surface antigen from a virus, and

b) a non-living vaccine antigen, said surface antigen having an adjuvant effect on said vaccine antigen,

wherein the surface antigen and vaccine antigen are each present up to about 1 mg.

12. The vaccine formulation according to claim 11, further comprising a preservative.

13. The vaccine formulation according to claim 11, further comprising a stabilizer.

14. The vaccine formulation according to claim 11, further comprising a second vaccine antigen.

15. The vaccine formulation according to claim 11, wherein the surface antigen is Hepatitis B virus surface antigen (HBsAg) and the vaccine antigen is an antigen of a viral nucleocapsid.

16. The vaccine formulation according to claim 15, wherein the viral nucleocapsid is a virus-like particle comprising the nucleocapsid antigen of Hepatitis B virus.

17. The vaccine formulation according to claim 15, wherein the viral nucleocapsid is a virus-like particle comprising the nucleocapsid antigen of Human Papilloma-virus.

18. The vaccine formulation according to claim 15, wherein the viral nucleocapsid is a virus-like particle comprising the nucleocapsid antigen of Hepatitis C virus.

19. (Amended) The vaccine formulation according to claim 11, wherein the surface antigen is Hepatitis B virus surface antigen (HBsAg) and the vaccine antigen comprises a single antigen or a mixture of different antigens that are immuno-enhanced by HBsAg.

20. The vaccine formulation according to claim 11, wherein the vaccine formulation is suitable for administration as a solid, liquid or spray.

21. (Amended) The vaccine formulation according to claim 11, wherein the vaccine formulation is suitable for nasal administration.

22. (Amended) The vaccine formulation according to claim 11, wherein the vaccine formulation is suitable for use as a therapeutic vaccine against Hepatitis B virus (HBV) infection.

B4

23. (Amended) The vaccine formulation according to claim 11, wherein the vaccine formulation is suitable for use as a preventive vaccine against Hepatitis B virus (HBV) infection.

D3 Subcl

24. (New) The vaccine formulation according to claim 11, wherein the vaccine formulation is suitable for use as a preventive vaccine against Hepatitis C virus (HCV) infection.

25. (New) The vaccine formulation according to claim 11, wherein the vaccine formulation is suitable for use as a preventive vaccine against Human Papilloma virus (HPV) infection.

B7

26. (New) The vaccine formulation according to claim 11, wherein the vaccine formulation is suitable for use as a therapeutic vaccine against Hepatitis C virus (HCV) infection.

27. (New) The vaccine formulation according to claim 11, wherein the vaccine formulation is suitable for use as a therapeutic vaccine against Human Papilloma virus (HPV) infection.

28. (New) The vaccine formulation according to claim 11, wherein the immune response to the surface antigen is enhanced.

29. (New) The vaccine formulation according to claim 11, wherein the immune response to said vaccine antigen is enhanced.

30. (New) The vaccine formulation according to claim 11, wherein the immune response to the surface antigen and to said vaccine antigen are each enhanced.

31. (New) The vaccine formulation according to claim 19, wherein the vaccine antigen comprises the core antigen of Hepatitis B virus.

32. (New) The vaccine formulation according to claim 19, wherein the vaccine antigen comprises the nucleocapsid antigen of Hepatitis C virus.

33. (New) The vaccine formulation according to claim 19, wherein the vaccine antigen comprises the nucleocapsid antigen of Human Papilloma-virus.